| Primary information |
|---|
| sequence ID | Seq_1250 |
| Peptide sequence | DFLAEGGGVR |
| CancerPDF_ID | CancerPDF_ID3, CancerPDF_ID645, CancerPDF_ID1021, CancerPDF_ID1209, CancerPDF_ID8507, CancerPDF_ID9655, CancerPDF_ID11378, CancerPDF_ID12755, |
| PMID | 16896061,19795908,16395409,21136997,23667664,21533267,26992070,26282206 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha chain,Fibrinopeptide A,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain,"FGA, Isoform 2 of Fibrinogen alpha chain" |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Serum,Plasma,Serum,Serum,Serum,Serum,Serum,Serum |
| M/Z | 1020.47,510.76,1020.47,1019.50361,1019.5,510.74,1019.5036,1025.5 |
| Charge | 1,2,1,1,1,2,NA,NA |
| Mass (in Da) | 1020.51,NA,NA,NA,1021.12,NA,1020.51201,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC-MS/MS,nano-LC/ESIeMS/MS |
| Quantification Technique | NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,NA,Multiple Reaction Monitoring,NA,NA |
| Labelled/Label Free | Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 7%,less than 1 “5,0.001,NA,1.49,FDR 1 %,NA |
| CancerPDF_ID | CancerPDF_ID3, CancerPDF_ID645, CancerPDF_ID1021, CancerPDF_ID1209, CancerPDF_ID8507, CancerPDF_ID9655, CancerPDF_ID11378, CancerPDF_ID12755, |
| p-Value | 1.00E-05,NA,1.67E-13,1.08E-05,NA,5.75E-25,NA,NA |
| Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,MASCOT,SEQUEST and Maxquant,BioworksBrowser |
| Length | 10,10,10,10,10,10,10,10 |
| Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Melanoma,Cervical cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,NA,Swissprot Database (57.4),SwissProt Database,IPI Human Database (3.45) |
| Modification | NA,NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy",30 patients and 30 healthy controls,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,8 cancer samples and 4 healthy samples,35 SCC patients (Cervical squamous cell carcinoma) and 20 healthy controls |
| Regulation | Differentially expressed between cancer vs normal samples,NA,"Downregulated in cancer vs normal with Ratio of median intensity (patients/Controls) = 0.28, 0.28 and 0.47 in prostate, bladder and breast cancer respectively",Differentially expressed between cancer vs normal,NA,Differentially expressed between Lung cancer vs control,"Present in 8 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples.",Upregulated in Cervical squamous cell carcinoma vs healthy |
| Validation | Independent validation,NA,Independent validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,na,NA |
| Sensitivity | 95% on independent dataset,NA,97.5% on independent validation dataset,0.898,NA,NA,NA,100 % on traning data and 80% on validation dataset |
| Specificity | 95% on independent dataset,NA,NA,0.946,NA,NA,NA,100% on training data and 100% on validation dataset |
| Accuracy | NA,NA,97.5 % on validation dataset,0.917,NA,0.677,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | 462581
|